Sartaj Tabassum

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4934103/publications.pdf

Version: 2024-02-01

138 papers	3,761 citations	109137 35 h-index	161609 54 g-index
139 all docs	139 docs citations	139 times ranked	3950 citing authors

#	Article	IF	Citations
1	Chemical and biotechnological developments in organotin cancer chemotherapy. Journal of Organometallic Chemistry, 2006, 691, 1761-1766.	0.8	188
2	Synthesis, characterization and interaction studies of copper based drug with Human Serum Albumin (HSA): Spectroscopic and molecular docking investigations. Journal of Photochemistry and Photobiology B: Biology, 2012, 114, 132-139.	1.7	167
3	Mixed-ligand Cu(II)â€“vanillin Schiff base complexes; effect of coligands on their DNA binding, DNA cleavage, SOD mimetic and anticancer activity. European Journal of Medicinal Chemistry, 2013, 60, 216-232.	2.6	120
4	Interaction and photo-induced cleavage studies of a copper based chemotherapeutic drug with human serum albumin: spectroscopic and molecular docking study. Molecular BioSystems, 2012, 8, 2424.	2.9	113
5	Synthesis and characterization of copper(II) and zinc(II)-based potential chemotherapeutic compounds: Their biological evaluation viz. DNA binding profile, cleavage and antimicrobial activity. European Journal of Medicinal Chemistry, 2012, 58, 308-316.	2.6	110
6	Organo-tin antitumor compounds: Their present status in drug development and future perspectives. Inorganica Chimica Acta, 2014, 423, 26-37.	1.2	95
7	Mechanistic insights into a novel chromone-appended Cu(<scp>ii</scp>) anticancer drug entity: in vitro binding profile with DNA/RNA substrates and cytotoxic activity against MCF-7 and HepG2 cancer cells. Dalton Transactions, 2015, 44, 10330-10342.	1.6	87
8	New modulated design and synthesis of quercetinâ€“CuII/ZnIIâ€“Sn2IV scaffold as anticancer agents: in vitro DNA binding profile, DNA cleavage pathway and Topo-I activity. Dalton Transactions, 2013, 42, 10029.	1.6	84
9	Current and future potential of metallo drugs: Revisiting DNA-binding of metal containing molecules and their diverse mechanism of action. Inorganica Chimica Acta, 2016, 444, 1-22.	1.2	79
10	Molecular drug design, synthesis and structure elucidation of a new specific target peptide based metallo drug for cancer chemotherapy as topoisomerase I inhibitor. Dalton Transactions, 2012, 41, 4955.	1.6	73
11	Synthesis and structure elucidation of a copper(II) Schiff-base complex: In vitro DNA binding, pBR322 plasmid cleavage and HSA binding studies. Journal of Photochemistry and Photobiology B: Biology, 2014, 140, 321-331.	1.7	66
12	Synthesis and spectroscopic characterization of diorganotin(<scp>iv</scp>) complexes of Nâ€²-(4-hydroxypent-3-en-2-ylidene)isonicotinohydrazide: chemotherapeutic potential validation by in vitro interaction studies with DNA/HSA, DFT, molecular docking and cytotoxic activity. RSC Advances, 2015, 5, 50673-50690.	1.7	66
13	Interaction of a ruthenium(II)â€“chalcone complex with double stranded DNA: Spectroscopic, molecular docking and nuclease properties. Journal of Photochemistry and Photobiology A: Chemistry, 2011, 220, 145-152.	2.0	63
14	Synthesis of new piperazine derived Cu(II)/Zn(II) metal complexes, their DNA binding studies, electrochemistry and anti-microbial activity: Validation for specific recognition of Zn(II) complex to DNA helix by interaction with thymine base. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2009, 72, 1026-1033.	2.0	61
15	Nuclear blebbing of biologically active organoselenium compound towards human cervical cancer cell (HeLa): InÂvitro DNA/HSA binding, cleavage and cell imaging studies. European Journal of Medicinal Chemistry, 2015, 90, 876-888.	2.6	61
16	Advancement of metal compounds as therapeutic and diagnostic metallodrugs: Current frontiers and future perspectives. Coordination Chemistry Reviews, 2021, 445, 214104.	9.5	59
17	Chiral heterobimetallic complexes targeting human DNA-topoisomerase IÎ±. Dalton Transactions, 2013, 42, 16749.	1.6	58
18	New modulated metallic macrocycles: Electrochemistry and their interaction with calf thymus DNA. Acta Biomaterialia, 2005, 1, 677-689.	4.1	57

#	Article	IF	Citations
19	Synthesis of heterobimetallic complexes: In vitro DNA binding, cleavage and antimicrobial studies. Journal of Photochemistry and Photobiology B: Biology, 2012, 114, 108-118.	1.7	56
20	Synthesis and crystal structure determination of copper(II)-complex: InÂvitro DNA and HSA binding, pBR322 plasmid cleavage, cell imaging and cytotoxic studies. European Journal of Medicinal Chemistry, 2014, 83, 141-154.	2.6	56
21	Development and future prospects of selective organometallic compounds as anticancer drug candidates exhibiting novel modes of action. European Journal of Medicinal Chemistry, 2019, 175, 269-286.	2.6	52
22	Synthesis and characterization of Cu(II)-based anticancer chemotherapeutic agent targeting topoisomerase IÎ±: InÂvitro DNA binding, pBR322 cleavage, molecular docking studies and cytotoxicity against human cancer cell lines. European Journal of Medicinal Chemistry, 2014, 74, 509-523.	2.6	51
23	Clinical developments of antitumor polymer therapeutics. RSC Advances, 2019, 9, 24699-24721.	1.7	47
24	Biochemical pathways of copper complexes: progress over the past 5 years. Drug Discovery Today, 2021, 26, 1086-1096.	3.2	47
25	Triphenyl Tin Benzimidazolethiol, a Novel Antitumor Agent, Induces Mitochondrial-Mediated Apoptosis in Human Cervical Cancer Cells via Suppression of HPV-18 Encoded E6. Journal of Biochemistry, 2003, 134, 521-528.	0.9	45
26	Carbohydrate linked organotin(<scp>iv</scp>) complexes as human topoisomerase IÎ± inhibitor and their antiproliferative effects against the human carcinoma cell line. Dalton Transactions, 2014, 43, 2534-2548.	1.6	45
27	Coumarin centered copper(<scp>ii</scp>) complex with appended-imidazole as cancer chemotherapeutic agents against lung cancer: molecular insight via DFT-based vibrational analysis. RSC Advances, 2017, 7, 36056-36071.	1.7	45
28	Template synthesis of novel carboxamide dinuclear copper (II) complex: spectral characterization and reactivity towards calf-thymus DNA. BioMetals, 2008, 21, 299-310.	1.8	44
29	New heterobimetallic complex as potential topoisomerase I inhibitor: In vitro DNA binding, cleavage and cytotoxicity against human cancer cell lines. Journal of Photochemistry and Photobiology B: Biology, 2012, 115, 63-72.	1.7	43
30	Heteroleptic Copper(I) Complexes of â€œScorpionateâ€•Bis-pyrazolyl Carboxylate Ligand with Auxiliary Phosphine as Potential Anticancer Agents: An Insight into Cytotoxic Mode. Scientific Reports, 2017, 7, 45229.	1.6	42
31	Synthesis, structural and spectroscopic characterization and biomimetic properties of new copper, manganese, zinc complexes: Identification of possible superoxide-dismutase mimics bearing hydroxyl radical generating/scavenging abilities. Journal of Inorganic Biochemistry, 2010, 104, 820-830.	1.5	41
32	A Chloro-Bridged Heterobimetallic (Î·⁶-Arene)ruthenium–Organotin Complex as an Efficient Topoisomerase IÎ± Inhibitor. Organometallics, 2013, 32, 2546-2551.	1.1	41
33	p53-Dependent Apoptotic Mechanism of a New Designer Bimetallic Compound Tri-phenyl Tin Benzimidazolethiol Copper Chloride (TPT-CuCl2): In Vivo Studies in Wistar Rats as Well as in Vitro Studies in Human Cervical Cancer Cells. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 22-33.	1.3	40
34	Organometallic ruthenium(II) scorpionate as topo IIÎ± inhibitor; inÂvitro binding studies with DNA, HPLC analysis and its anticancer activity. Journal of Organometallic Chemistry, 2014, 771, 47-58.	0.8	39
35	Multispectroscopic insight, morphological analysis and molecular docking studies of CuII-based chemotherapeutic drug entity with human serum albumin (HSA) and bovine serum albumin (BSA). Journal of Biomolecular Structure and Dynamics, 2019, 37, 3290-3304.	2.0	39
36	Biological evaluation of dinuclear copper complex/dichloroacetic acid cocrystal against human breast cancer: design, synthesis, characterization, DFT studies and cytotoxicity assays. RSC Advances, 2017, 7, 47920-47932.	1.7	38

#	Article	IF	Citations
37	Synthesis and structure elucidation of a cobalt(II) complex as topoisomerase I inhibitor: InÂvitro DNA binding, nuclease and RBC hemolysis. European Journal of Medicinal Chemistry, 2014, 74, 683-693.	2.6	36
38	Design and synthesis of (S)- and (R)-enantiomers of [4-(2-hydroxy-1-phenylethylimino)pent-2-ol]dimethyltin(<scp>iv</scp>) and 2,2-dimethyl-4-phenyl-1,3,2-oxazastannolidine: in vitro antitumor activity against human tumor cell lines and in vivo assay of (S)-enantiomers. Dalton Transactions, 2013, 42, 3390-3401.	1.6	35
39	Title is missing!. Transition Metal Chemistry, 2001, 26, 426-429.	0.7	33
40	Structure elucidation {spectroscopic, single crystal X-ray diffraction and computational DFT studies} of new tailored benzenesulfonamide derived Schiff base copper(II) intercalating complexes: Comprehensive biological profile {DNA binding, pBR322 DNA cleavage, Topo I inhibition and cytotoxic activity}. Bioorganic Chemistry, 2020, 94, 103427.	2.0	32
41	Synthesis of carbohydrate-conjugate heterobimetallic CuIIâ€“Sn2IV and ZnIIâ€“Sn2IV complexes; their interactions with CT DNA and nucleotides; DNA cleavage, in-vitro cytotoxicity. European Journal of Medicinal Chemistry, 2010, 45, 4797-4806.	2.6	31
42	A multifunctional molecular entity Cu^{II}â€“Sn^{IV} heterobimetallic complex as a potential cancer chemotherapeutic agent: DNA binding/cleavage, SOD mimetic, topoisomerase Iα inhibitory and in vitro cytotoxic activities. RSC Advances, 2015, 5, 47439-47450.	1.7	31
43	Identification of a Potent Inhibitor of Human Dualâ€Specific Phosphatase, VHR, from Computerâ€Aided and NMRâ€Based Screening to Cellular Effects. ChemBioChem, 2007, 8, 2092-2099.	1.3	30
44	Recent advances in metallodrug-like molecules targeting non-coding RNAs in cancer chemotherapy. Coordination Chemistry Reviews, 2019, 387, 47-59.	9.5	30
45	DNA interaction studies of new nano metal based anticancer agent: validation by spectroscopic methods. Nanotechnology, 2010, 21, 195102.	1.3	29
46	Evaluation of cytotoxic potential of structurally well-characterized RNA targeted ionic non-steroidal anti-inflammatory (NSAID) Cu(<scp>ii</scp>) & Zn(<scp>ii</scp>) DACHâ€“mefenamato drug conjugates against human cancer cell lines. RSC Advances, 2020, 10, 166-178.	1.7	29
47	â€œTurnâ€onâ€•benzophenone based fluorescence and colorimetric sensor for the selective detection of Fe2+ in aqueous media: Validation of sensing mechanism by spectroscopic and computational studies. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2021, 247, 119156.	2.0	29
48	Design, synthesis, characterization and DNA-binding studies of a triphenyltin(iv) complex of N-glycoside (GATPT), a sugar based apoptosis inducer: in vitro and in vivo assessment of induction of apoptosis by GATPT. Metallomics, 2012, 4, 205-217.	1.0	28
49	Synthesis and characterization of glycoconjugate tin(IV) complexes: In vitro DNA binding studies, cytotoxicity, and cell death. Journal of Organometallic Chemistry, 2011, 696, 1600-1608.	0.8	26
50	Coumarin Derived â€œTurn onâ€•Fluorescent Sensor for Selective Detection of Cadmium (II) Ion: Spectroscopic Studies and Validation of Sensing Mechanism by DFT Calculations. Journal of Fluorescence, 2019, 29, 1029-1037.	1.3	26
51	Synthesis of chiral R/S-pseudopeptide-based Cu(<scp>ii</scp>) & Zn(<scp>ii</scp>) complexes for use in targeted delivery for antitumor therapy: enantiomeric discrimination with CT-DNA and pBR322 DNA hydrolytic cleavage mechanism. RSC Advances, 2017, 7, 6587-6597.	1.7	25
52	Water soluble ionic Co(<scp>ii</scp>), Cu(<scp>ii</scp>) and Zn(<scp>ii</scp>) diimineâ€“glycinate complexes targeted to tRNA: structural description, in vitro comparative binding, cleavage and cytotoxic studies towards chemoresistant prostate cancer cells. Dalton Transactions, 2020, 49, 16830-16848.	1.6	24
53	Enantiomeric Specificity of Biologically Significant Cu(II) and Zn(II) Chromone Complexes Towards DNA. Chirality, 2012, 24, 977-986.	1.3	23
54	Chiral transition metal complexes: Synthetic approach and biological applications. Inorganica Chimica Acta, 2017, 458, 8-27.	1.2	23

#	Article	IF	Citations
55	Design and synthesis of a DNA intercalative half-sandwich organoruthenium(<scp>ii</scp>)â€“chromone complex: cytotoxicity evaluation and topoisomerase Î± inhibition assay. New Journal of Chemistry, 2019, 43, 5475-5487.	1.4	22
56	Chelating behaviour of new 12-membered Schiff base macrocycles containing pendant groups. Transition Metal Chemistry, 1995, 20, 13.	0.7	21
57	De novo design of chiral organotin cancer drug candidates: Validation of enantiopreferential binding to molecular target DNA and 5â€²-GMP by UVâ€“visible, fluorescence, 1H and 31P NMR. Journal of Photochemistry and Photobiology B: Biology, 2011, 105, 167-174.	1.7	21
58	Carbohydrate-conjugate heterobimetallic complexes: synthesis, DNA binding studies, artificial nuclease activity and in vitro cytotoxicity. Carbohydrate Research, 2011, 346, 2886-2895.	1.1	21
59	DNA binding and cleavage studies of new sulfasalazine-derived dipeptide Zn(II) complex: Validation for specific recognition with 5â€²â€“TMP. Journal of Luminescence, 2012, 132, 3058-3065.	1.5	20
60	Synthesis and characterization of Co(<scp>ii</scp>) and Fe(<scp>ii</scp>) peptide conjugates as hydrolytic cleaving agents and their preferential enantiomeric disposition for CT-DNA: structural investigation of <scp>l</scp>-enantiomers by DFT and molecular docking studies. RSC Advances, 2015, 5, 72121-72131.	1.7	20
61	A comparative analyses of bioactive Cu(II) complexes using Hirshfeld surface and density functional theory (DFT) methods: DNA binding studies, cleavage and antibiofilm activities. Inorganica Chimica Acta, 2016, 453, 193-201.	1.2	20
62	Single X-ray crystal structure, DFT studies and topoisomerase I inhibition activity of a tailored ionic Ag(<scp>i</scp>) nalidixic acidâ€“piperazinium drug entity specific for pancreatic cancer cells. New Journal of Chemistry, 2018, 42, 506-519.	1.4	20
63	Synthesis and Characterization of a New Macrocyclic Copper(II) Complex with anN-Glycosidic Pendant Arm:in vitro Cytotoxicity and Binding Studies with Calf-Thymus DNA. Chemistry and Biodiversity, 2006, 3, 312-325.	1.0	19
64	Human Topoisomerase I mediated cytotoxicity profile of l-valine-quercetin diorganotin(IV) antitumor drug entities. Journal of Organometallic Chemistry, 2016, 823, 23-33.	0.8	19
65	Synthesis and enantiopreferential DNAâ€binding profile of late 3d transition metal Râ€•and Sâ€enantiomeric complexes derived from N,Nâ€bisâ€(1â€benzylâ€2â€ethoxyethane): Validation of Râ€enantiomer of copper(II) complex as a human topoisomerase II inhibitor. Chirality, 2011, 23, 557-567.	1.3	18
66	Investigation of diorganotin(IV) complexes: Synthesis, characterization, in vitro DNA binding studies and cytotoxicity assessment of di-n-butyltin(IV) complex. Inorganica Chimica Acta, 2014, 423, 204-214.	1.2	18
67	A dinuclear copper(II) complex with piperazine bridge ligand as a potential anticancer agent: DFT computation and biological evaluation. Inorganica Chimica Acta, 2016, 445, 167-178.	1.2	18
68	New homodi-and heterotrinuclear metal complexes of Schiff base compartmental ligand: interaction studies of copper complexes with calf thymus DNA. Open Chemistry, 2006, 4, 502-522.	1.0	17
69	Cyclic Voltammetry-An Electrochemical Approach to Study Metal-based Potential Antitumor Drug-DNA Interaction. Current Analytical Chemistry, 2011, 7, 71-79.	0.6	17
70	New modulated design, docking and synthesis of carbohydrate-conjugate heterobimetallic CuIIâ€“SnIV complex as potential topoisomerase II inhibitor: InÂvitro DNA binding, cleavage and cytotoxicity against human cancer cell lines. European Journal of Medicinal Chemistry, 2014, 74, 694-702.	2.6	17
71	Cu(II) complexes as receptor molecules for development of new chloride sensors. Electrochimica Acta, 2006, 52, 408-414.	2.6	16
72	Tetranuclear cubane Cu4O4 complexes as prospective anticancer agents: Design, synthesis, structural elucidation, magnetism, computational and cytotoxicity studies. Inorganica Chimica Acta, 2018, 473, 121-132.	1.2	16

#	Article	IF	Citations
73	Exploration of glycosylated-organotin(IV) complexes as anticancer drug candidates. Inorganica Chimica Acta, 2014, 423, 38-45.	1.2	15
74	Synthesis and crystal structure elucidation of new copper(II)-based chemotherapeutic agent coupled with 1,2-DACH and orthovanillin: Validated by in vitro DNA/HSA binding profile and pBR322 cleavage pathway. Journal of Photochemistry and Photobiology B: Biology, 2016, 161, 318-327.	1.7	15
75	Carbohydrate-based heteronuclear complexes as topoisomerase Iα inhibitor: approach toward anticancer chemotherapeutics. Journal of Biomolecular Structure and Dynamics, 2019, 37, 1494-1510.	2.0	15
76	A chromone-based colorimetric fluorescence sensor for selective detection of Cu2+ions, and its application for in-situ imaging. Journal of Molecular Structure, 2022, 1256, 132533.	1.8	15
77	Cu II -Na I heteronuclear complex as anticancer entity against human breast cancer cell lines: DNA binding, cleavage, and Computational studies. Inorganica Chimica Acta, 2018, 479, 229-239.	1.2	14
78	Spectroscopic and singleâ€crystal Xâ€ray diffraction studies of enantiomeric copper(II) Schiff base oneâ€dimensional coordination polymers with 4â€(2â€aminoethyl)benzenesulfonamide appendage: Comprehensive biological evaluation (DNA binding, cleavage, superoxide dismutase mimetic activity,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.7	14
79	Heterobimetallic o-vanillin functionalized complexes: InÂvitro DNA binding validation, cleavage activity and molecular docking studies ofÂCuIIâ€“Sn2IV analogs. Journal of Organometallic Chemistry, 2014, 752, 17-24.	0.8	13
80	Synthesis and crystal structure determination of a mononuclear cobalt(<scp>ii</scp>) complex derived from 4-(pyridin-4-ylmethoxy)-benzoic acid: evaluation of the DNA/protein interaction and photo-induced pBR322 DNA cleavage. RSC Advances, 2015, 5, 35843-35851.	1.7	13
81	Structural, Spectroscopic, and Chemical Bonding Analysis of Zn(II) Complex [Zn(sal)](H2O): Combined Experimental and Theoretical (NBO, QTAIM, and ELF) Investigation. Crystals, 2020, 10, 259.	1.0	13
82	Title is missing!. Transition Metal Chemistry, 2002, 27, 741-747.	0.7	12
83	Synthesis of Aryl-1,2,4,5-tetrazinane-3-thiones, in vitro DNA binding studies, nuclease activity and its antimicrobial activity. Journal of Molecular Structure, 2012, 1020, 33-40.	1.8	12
84	Evaluation of cytotoxic activity and genotoxicity of structurally well characterized potent cobalt(II) phenâ€based antitumor drug entities: An in vitro and in vivo approach. Bioorganic Chemistry, 2019, 88, 102963.	2.0	12
85	Modulation of amyloid fibril formation of plasma protein by saffron constituent â€œsafranalâ€: Spectroscopic and imaging analyses. International Journal of Biological Macromolecules, 2019, 127, 529-535.	3.6	12
86	SYNTHESIS, CHARACTERIZATION, AND TOXICITY OF HETEROBINUCLEAR COMPLEXES OF TRANSITION METAL IONS. Synthesis and Reactivity in Inorganic, Metal Organic, and Nano Metal Chemistry, 2001, 31, 1803-1815.	1.8	11
87	New modulated design and synthesis of chiral CuII/SnIV bimetallic potential anticancer drug entity: In vitro DNA binding and pBR322 DNA cleavage activity. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2012, 90, 208-217.	2.0	11
88	Synthesis, structure elucidation and DFT studies of a new coumarin-derived Zn(<scp>ii</scp>) complex: in vitro DNA/HSA binding profile and pBR322 cleavage pathway. RSC Advances, 2014, 4, 43504-43515.	1.7	11
89	Loss of DUSP3 activity radiosensitizes human tumor cell lines via attenuation of DNA repair pathways. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 1879-1894.	1.1	11
90	New Ionic Cu(II) and Co(II) DACHâ€“Flufenamate Conjugate Complexes: Spectroscopic Characterization, Single Xâ€“Ray Studies and Cytotoxic Activity on Human Cancer Cell Lines. ChemistrySelect, 2018, 3, 12764-12772.	0.7	11

#	Article	IF	Citations
91	Metal complexes of NSAIDs as potent anti-tumor chemotherapeutics: Mechanistic insights into cytotoxic activity via multiple pathways primarily by inhibition of COXâ€“1 and COXâ€“2 enzymes. Coordination Chemistry Reviews, 2022, 453, 214316.	9.5	11
92	Synthesis and mechanistic insight of glycosylated CuII/NiIIâ€“Sn2IV heterobimetallic DNA binding agents: Validation of a specific CuIIâ€“Sn2IV chemotherapeutic agent for human leukemic cell line K-562. Journal of Organometallic Chemistry, 2013, 745-746, 226-234.	0.8	10
93	Synthesis and structure elucidation of new open cubane tetranuclear [Cu II 4] Cluster: Evaluation of the DNA/HSA interaction and pBR322 DNA cleavage pathway and cytotoxicity. Inorganica Chimica Acta, 2017, 463, 142-155.	1.2	10
94	Î²-Carboline Silver Compound Binding Studies with Human Serum Albumin: A Comprehensive Multispectroscopic Analysis and Molecular Modeling Study. Bioinorganic Chemistry and Applications, 2018, 2018, 1-11.	1.8	10
95	Evaluation of (É³⁶-pcymene) ruthenium diclofenac complex as anticancer chemotherapeutic agent: interaction with biomolecules, cytotoxicity assays. Journal of Biomolecular Structure and Dynamics, 2019, 37, 3905-3913.	2.0	10
96	Synthesis and characterization of heterobimetallic SnIVâ€“CuII/ZnII complexes: DFT studies, cleavage potential and cytotoxic activity. Journal of Biomolecular Structure and Dynamics, 2020, 38, 1130-1142.	2.0	10
97	Comprehensive biological {DNA/RNA binding profile, cleavage &cytotoxicity activity} of structurally well-characterized chromone-appended Cu(II)(L1-3)(phen) potential anticancer drug candidates. Polyhedron, 2022, 214, 115638.	1.0	10
98	Synthesis, Characterization, Solution Stability Studies, Electrochemistry, and DNAâ€Binding Behavior of Cu(II) Complexes of<scp>D</scp>â€Gluconic Acid. Journal of Carbohydrate Chemistry, 2005, 24, 865-887.	0.4	9
99	Chiral nano heterobimetallic DNA receptors: InÂvitro binding studies, cleavage activity and DNA condensation studies (TEM and AFM imaging). Journal of Organometallic Chemistry, 2012, 713, 123-133.	0.8	9
100	A zwitterionic Zn(II) benzothiazole nanohybrid conjugate as hydrolytic DNA cleavage agent. Inorganic Chemistry Communication, 2018, 93, 69-72.	1.8	9
101	Synthesis, structural investigations and DNA cleavage properties of a new water soluble Cu(II)â€“iminodiacetate complex. Inorganic Chemistry Communication, 2019, 106, 48-53.	1.8	9
102	Title is missing!. Transition Metal Chemistry, 2001, 26, 574-580.	0.7	8
103	DNA binding, docking studies, artificial nuclease activity and in vitro cytotoxicity of newly synthesized steroidal 1Hâ€“pyrimidines. Comptes Rendus Chimie, 2014, 17, 359-369.	0.2	8
104	Structure elucidation, in vitro binding studies and ROS-dependent anti-cancer activity of Cu(II) and Zn(II) phthaloylglycinate(phen) complexes against MDA-MB-231 cells. Metallomics, 2021, 13, .	1.0	8
105	Interaction of a new cobalt(II) complex of five-coordinated chiral porphyrin with calf thymus DNA. Transition Metal Chemistry, 2002, 27, 256-261.	0.7	7
106	Synthesis and characterization of new synthetic oxygen carriers. A kinetic study of the reaction of the binuclear iron(III)?copper(II) complex with H2O2. Transition Metal Chemistry, 2005, 30, 196-204.	0.7	7
107	Fluorescent delivery vehicle containing cobalt oxideâ€“umbelliferone nanoconjugate: DNA/protein interaction studies and anticancer activity on MF7 cancer cell line. RSC Advances, 2019, 9, 26503-26518.	1.7	7
108	Biophysical binding profile with ct-DNA and cytotoxic studies of a modulated nanoconjugate of umbelliferone cobalt oxide loaded on graphene oxide (GO) as drug carrier. Journal of Biomolecular Structure and Dynamics, 2022, 40, 4558-4569.	2.0	7

#	Article	IF	Citations
109	Synthesis of new heterometallic macromolecules: Their DNA binding, cleavage activity and in vitro model electrochemotherapy study. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2009, 74, 1152-1159.	2.0	6
110	Cadmiumâ€induced neurodegeneration and activation of noncanonical sonic hedgehog pathway in rat cerebellum. Journal of Biochemical and Molecular Toxicology, 2019, 33, e22274.	1.4	6
111	Structural characterization, theoretical investigation and sensing activity of a novel Cu(II)â€“based 1D metal coordination polymer. Inorganic Chemistry Communication, 2021, 126, 108473.	1.8	6
112	Design, synthesis, ligandâ€™s scaffold variation and structure elucidation of Cu(II) complexes; In vitro DNA binding, morphological studies and their anticancer activity. Polyhedron, 2021, 209, 115450.	1.0	6
113	An MCl inf4 p2? moiety (M = copper, zinc, cadmium and mercury) stabilized by bis(ethylenediamine)copper(II) cation. Transition Metal Chemistry, 1995, 20, 123.	0.7	5
114	Organometallic ruthenium (Î·⁶-p-cymene) complexes interfering with quorum sensing and biofilm formation: an anti-infective approach to combat multidrug-resistance in bacteria. New Journal of Chemistry, 2021, 45, 2184-2199.	1.4	5
115	Elucidating the interaction of enantiomeric Cu(II) complexes with DNA, RNA and HSA: A comparative study. Polyhedron, 2021, 210, 115501.	1.0	5
116	A novel biocompatible formate bridged 1D-Cu(<scp>ii</scp>) coordination polymer induces apoptosis selectively in human lung adenocarcinoma (A549) cells. Dalton Transactions, 2021, 50, 2253-2267.	1.6	5
117	Chromoneâ€Appended Zn(II) tRNAâ€Targeted Potential Anticancer Chemotherapeutic Agent: Structural Details, inâ€…vitro ctâ€DNA/tRNA Binding, Cytotoxicity Studies And Antioxidant Activity. ChemistrySelect, 2022, 7, .	0.7	5
118	Synthesis and crystal structure determination of cobalt(II) mixed-ligand complex containing 1,10-phenanthroline and 5-(2-carboxybenzyloxy)isophthalic acid: Their biological evaluation viz. DNA/protein binding profile, pBR322 DNA cleavage activity. Inorganica Chimica Acta, 2016, 451, 216-226.	1.2	4
119	Synthesis of homo- and hetero-metallic cobalt and zinc nano oxide particles by a calcination process using coordination compounds: their characterization, DFT calculations and capacitance behavioural study. RSC Advances, 2020, 10, 13126-13138.	1.7	4
120	Synthesis, Structure Elucidation by Multi-spectroscopic Techniques and Single-crystal X-ray Diffraction of Promising Fluoro/Bromo-substituted-chromone(bpy)copper(II) Anticancer Drug Entities. Inorganica Chimica Acta, 2022, , 120967.	1.2	4
121	Synthesis, structural insights, biological screening of DNA targeted Ru(â…¡)(Æž6-p-cymene) complexes containing bioactive amino-benzothiazole ligand scaffolds. New Journal of Chemistry, 0, , .	1.4	4
122	Synthesis of new dinuclear dicopper(II) and dinickel(II) complexes. The kinetics of catechol oxidase and electrochemistry of a dicopper(II) complex. Transition Metal Chemistry, 2005, 30, 128-135.	0.7	3
123	Novel Bimetallic Complexes of Copper, Nickel and Manganese Derived from the Cobalt(III) Complex and their Interaction Studies with Calf Thymus DNA. Transition Metal Chemistry, 2005, 30, 998-1007.	0.7	3
124	Synthesis and Characterization of Glucose-Bis(pyrazole)-Cu(II)/Ni(II) Complexes and Their in Vitro DNA Binding Studies. Chemical and Pharmaceutical Bulletin, 2010, 58, 318-325.	0.6	3
125	Deciphering the effect of hydrophobicity on protein binding interaction in cobalt(II) complexes by multispectroscopic and computational methods. Journal of Biomolecular Structure and Dynamics, 2022, 40, 7381-7393.	2.0	3
126	Synthesis, structural characterization, in vitro comparative DNA/RNA binding, and computational studies of half-sandwich Ru (II)(Æž6-p-cymene) aminoquinoline complex. Polyhedron, 2022, 213, 115618.	1.0	3

#	Article	IF	Citations
127	New metal compounds and their reactivity towards bovine milk casein. Transition Metal Chemistry, 2002, 27, 776-781.	0.7	2
128	Catalytic induced morpholical transformation of porous ZnO to ZnO nanorods by Sn(IV) and their effect on photocatalytic reduction of methylene blue and DFT calculations. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2019, 220, 117101.	2.0	2
129	Multi-Component One-Pot Assisted Synthesis, Anti-bacterial Capabilities, and Scanning Electron Microscopy of Novel Corticosteroid Thiopyran. Current Organic Synthesis, 2021, 18, 411-417.	0.7	2
130	Functionalized graphene oxide loaded GATPT as rationally designed vehicle for cancer-targeted drug delivery. Journal of Drug Delivery Science and Technology, 2022, 71, 103281.	1.4	2
131	Synthesis of new 14- and 16-membered macrocycles and their transition metal complexes. Transition Metal Chemistry, 1996, 21, 97-100.	0.7	1
132	Synthesis and Characterization of the Copper(II) Complex with 2,2â€bis(1H,3H,5H)Pyrimidineâ€4,6â€dioneâ€1,2â€diiminoethane: Fluorescence Quenching Studies in Proteins. Synthesis and Reactivity in Inorganic, Metal Organic, and Nano Metal Chemistry, 2003, 33, 509-517.	1.8	1
133	Synthesis of O,O Ethane Bridged Bis-copper(II) Macrocycles. Selective Enzyme Model for Catecholase Activity. Transition Metal Chemistry, 2006, 31, 237-245.	0.7	1
134	Structure of Imidazolium-N-phthalolylglycinate Salt Hydrate: Combined Experimental and Quantum Chemical Calculations Studies. Crystals, 2020, 10, 91.	1.0	1
135	Interaction of Carrier Protein with Potential Metallic Drug Candidate N-Glycoside â€˜GATPTâ€™: Validation by Multi-Spectroscopic and Molecular Docking Approaches. Molecules, 2021, 26, 6641.	1.7	1
136	Comprehensive structural {single crystal X-raydiffraction, spectroscopic & DFT computational simulation} and biological {in vitro DNA binding & antibacterial} studies of polymeric copper(â…¡)-based imidazole drug entity. Inorganica Chimica Acta, 2022, 538, 120978.	1.2	1
137	N2S2 macrocyclic ligands. Synthesis and characterization of novel transition metal complexes of the type [LM(Si2Me6NH)2]2+ and [L?M(Si2Me6NH)2]2+. Transition Metal Chemistry, 1994, 19, 399.	0.7	0
138	ROS -mediated anticancer response of potent copper(II) drug entities derived from S, O and N, N chelating donor scaffold: Single X-ray crystal diffraction and spectroscopic studies. Journal of Molecular Structure, 2022, , 132989.	1.8	0